Core Insights - Konomai (Beijing) Technology Co., Ltd. has completed several million yuan in A+ round financing, led by Jiuan Medical, to accelerate commercialization and continue independent research and innovation [3] - The Chinese analytical instrument market heavily relies on imports, with annual import value around $100 billion, particularly in liquid chromatography as the leading product [3] - Konomai, established in 2019, focuses on the independent research and industrialization of ultra-high-performance liquid chromatography (UHPLC) technology, with a core founding team averaging nearly 20 years of experience in life science instruments [3][4] - The company has achieved a 95% localization rate for product components as of 2022, with a full series of UHPLC products developed [4] Company Performance - Since the start of its commercialization in 2023, Konomai has maintained an annual sales growth rate exceeding 50%, with overseas market growth surpassing 80% [5] - The company has expanded its customer base to hundreds across over 20 countries and regions, covering various fields such as drug analysis, biosynthesis, academic research, food safety, and environmental protection [5] Investment Perspective - Jiuan Medical's chairman, Liu Yi, emphasizes the focus on practical enterprises that can address industry pain points and lead industrial upgrades, highlighting Konomai's role in breaking the long-standing reliance on imports in the high-end market of ultra-high-performance liquid chromatography [6]

Core Viewpoint - The article highlights the significant advancements and growth of Konomai (Beijing) Technology Co., Ltd. in the high-end scientific instrument sector, particularly in the field of ultra-high-performance liquid chromatography (UHPLC), emphasizing its role in the domestic market's shift towards self-sufficiency and reduced reliance on imports [2][5]. Group 1: Company Overview - Konomai has completed a multi-million A+ round of financing led by Jiuan Medical, with funds aimed at accelerating commercialization and continuous innovation in independent research and development [2]. - Founded in 2019, Konomai focuses on the independent research and industrialization of UHPLC technology, with its core founding team averaging nearly 20 years of experience in the life science instrument field [2]. - The company has applied for over 30 patents and software copyrights, including 6 invention patents and 14 utility model patents, as of April 2025 [2]. Group 2: Product and Market Position - Konomai has achieved a 95% localization rate for its product components, significantly contributing to the reduction of procurement costs and enhancing analysis efficiency for clients [3]. - The company has launched a full series of UHPLC products, including automated IVD two-dimensional liquid chromatography systems and intelligent chromatography data management systems [2]. - Since initiating its commercialization strategy in 2023, Konomai has experienced a sales growth rate exceeding 50% annually, with international market growth surpassing 80% [3][4]. Group 3: Investment Perspective - Jiuan Medical's chairman, Liu Yi, emphasizes the importance of collaborating with practical enterprises that can address industry pain points and lead industrial upgrades, focusing on self-research and the domestic scientific instrument market [5]. - Konomai's advancements in the UHPLC sector are seen as pivotal in breaking the long-standing reliance on imports in China's high-end market [5].

Core Insights - Konomai has completed a strategic A+ round financing of several tens of millions, focusing on the R&D of high-end ultra-high-performance liquid chromatography (UHPLC) instruments to accelerate the domestic substitution process and build a comprehensive solution with a domestic component localization rate of 95% [1][2]. Technological Breakthroughs - Since its establishment in 2019, Konomai has focused on "positive independent R&D" and has become a leading enterprise in the domestic UHPLC technology field. The Frontier UHPLC system launched in 2023 has won multiple industry awards, including the BCEIA Gold Award. By 2025, the company aims to upgrade its ultra-high pressure dual pump UP26T and quad pump UP40, making it the second global manufacturer to achieve a pressure resistance of 20,000 psi (1380 Bar) [5][6]. Commercialization Strategy - Konomai has seen an average annual growth rate of over 50% since starting commercialization in 2023, with overseas market growth exceeding 80%. Its products are now available in over 20 countries and regions, serving hundreds of global clients. The company covers key areas such as drug analysis, biosynthesis, academic research, food safety, and environmental protection, helping clients reduce costs and improve efficiency through the localization of high-end equipment [6][7]. Capital Empowerment - Jiuan Medical's chairman, Liu Yi, emphasized that valuable investments are not just about capital accumulation but about collaborating with practical enterprises that can address industry pain points and lead industrial upgrades. The investment in Konomai is based on its ability to break the long-standing reliance on imports in the high-end UHPLC market, with Jiuan Medical aiming to leverage resource synergy and strategic empowerment to help Konomai overcome technical challenges and seize domestic substitution opportunities [7].

Core Insights - Konomai (Beijing) Technology Co., Ltd. has completed A+ round financing of several tens of millions, led by Jiuan Medical, to accelerate commercialization and continue independent R&D [1][2] - The Chinese analytical instrument market heavily relies on imports, with annual import value around $100 billion, particularly in liquid chromatography, which is the leading product in chemical analysis and life sciences [1] - Konomai, established in 2019, focuses on the independent R&D and industrialization of ultra-high-performance liquid chromatography (UHPLC) technology, with a core founding team averaging nearly 20 years of experience in life science instruments [1][2] Company Developments - Konomai has completed a full series layout of UHPLC products, including automated IVD two-dimensional liquid chromatography systems and intelligent chromatography data management systems [1] - The company has initiated the construction of a production base in Suzhou since 2022, achieving a domestic component localization rate of 95% [2] - Konomai's sales revenue has been growing at over 50% annually since the start of its commercialization layout in 2023, with overseas market growth exceeding 80% [2] Investment Perspective - Jiuan Medical aims to discover and collaborate with practical enterprises that can address industry pain points and lead industrial upgrades, focusing on deepening independent R&D and leveraging the "Stanford model" [3] - The company emphasizes the importance of the domestic scientific instrument localization trend and policy support to promote import substitution in the global market [3] - Konomai's breakthroughs in the UHPLC field are breaking the long-standing reliance on imports in China's high-end market [3]